Showing results (151-160 of 1,150) with videos related to
Sort By:
Pageof 115
Comprehensive Psychiatry|August 24, 2010
A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorderSeetal Dodd, Alan J M Brnabic, Lesley Berk, et al.Journal of Affective Disorders|August 18, 2012
The sick role, illness cognitions and outcomes in bipolar disorderMichael Berk, Lesley Berk, Seetal Dodd, et al.Human Psychopharmacology|March 31, 2009
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trialMichael Berk, Clarissa S Gama, Suresh Sundram, et al.Psychiatric Genetics|March 19, 2014
Genetic polymorphisms in glutathione-S-transferases are associated with anxiety and mood disorders in nicotine dependenceSandra Odebrecht Vargas Nunes, Márcia Regina Pizzo de Castro, Maria Angelica Ehara Watanabe, et al.Biological Psychiatry|December 25, 2012
Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and functionJason M Hodge, Yiming Wang, Michael Berk, et al.Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 29, 2019
Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled TrialMelanie M Ashton, Mohammadreza Mohebbi, Alyna Turner, et al.Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|March 26, 2019
Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostanaLinn. (Mangosteen) Pericarp for SchizophreniaAlyna Turner, John J McGrath, Olivia M Dean, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 3, 2022
The role of metformin as a treatment for neuropsychiatric illnessSeetal Dodd, Luba Sominsky, Dan Siskind, et al.Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 23, 2020
Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placeboAlyna Turner, Andrea Baker, Olivia M Dean, et al.Acta Psychiatrica Scandinavica|July 13, 2024
Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta-analysisAnna Giménez-Palomo, Anjli K Chamdal, Natalie Gottlieb, et al.Pageof 115